Curanex Pharmaceuticals Inc (NASDAQ:CURX) Short Interest Update

Curanex Pharmaceuticals Inc (NASDAQ:CURX) was the target of a large decline in short interest in August. As of August 31st, there was short interest totaling 449 shares, a decline of 98.2% from the August 15th total of 24,375 shares. Approximately 0.0% of the shares of the stock are sold short. Based on an average daily trading volume, of 35,024 shares, the days-to-cover ratio is presently 0.0 days.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Curanex Pharmaceuticals in a report on Wednesday, July 29th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Sell”.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Curanex Pharmaceuticals stock. Citadel Advisors LLC bought a new stake in Curanex Pharmaceuticals Inc (NASDAQ:CURX) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 64,067 shares of the company’s stock, valued at approximately $46,000.

Curanex Pharmaceuticals Stock Performance

Curanex Pharmaceuticals stock traded up $0.17 during midday trading on Friday, hitting $4.49. 7,357 shares of the company’s stock were exchanged, compared to its average volume of 34,650. The company has a market cap of $7.04 million and a P/E ratio of -0.57. The stock has a 50-day moving average price of $4.35 and a two-hundred day moving average price of $6.45. Curanex Pharmaceuticals has a 52-week low of $3.58 and a 52-week high of $183.59.

About Curanex Pharmaceuticals

Curanex is a developmental stage pharmaceutical company dedicated to discovering, developing and commercializing innovative botanical drugs to treat patients suffering from inflammatory diseases. Our mission is to address significant unmet medical needs and improve patients’ lives by harnessing the power of natural substances. We are dedicated to discovering, developing and commercializing botanical medicines for treating patients with immune and inflammatory diseases and to develop therapies that may offer potential benefits to patients with unmet clinical needs in various fields, such as autoimmune diseases, metabolic diseases and viral infections.